Pancreatic cancer
Conditions
Interventions
Resected tumor-pulsed dendritic cells or MUC-1 peptide-pulsed dendritic cells
Sponsors
Yokohama City University, Gastroenterological Surgery
Seta clinic group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with histologically diagnosed and informed pancreatic cancer. (2)Patients with 20 years of age or older. (3)Patients with resectable or resected pancreatic cancer. (4)Tumors expressed MHC class1 or MUC-1. (5)Patients with PS0-2. (6)Patients can visit seta clinic. (7)Patients with expected survival of 3 months or longer. (8)Patients with no bone-marrow, liver or renal dysfunction. (9)Patients can be conducted apheresis. (10)Written informed consent from patients.
Exclusion criteria
Exclusion criteria: (1)Patients with sighs or history of interstitial pneumonia. (2)Patients with autoimmune diseases. (3)Patients with uncontrolable infectious diseases. (4)Patients with history of severe heart diseases. (5)Patients with history of severe drug allergy. (6)Patients received continuous administration of steroids. (7)Patients with pregnant or probability of pregnancy or breast-feeding. (8)Patients with HIV or HTLV-1 infection in 6 months. (9)Patients considered inadequate for this trial by physician-in-charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor-specific immune responses | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse free survival Overall survival Tumor marker Quality of life | — |
Countries
Japan
Outcome results
None listed